MANGOCEUTICALS INC
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
MGRX$0.19+1.6%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The following exhibits are filed herewith or incorporated by reference herein:
| Filed/ · Incorporated by Reference | |||||
|---|---|---|---|---|---|
| Exhibit · Description of · Furnished · Filing · File | |||||
| Number · Exhibit · Herewith · Form · Exhibit · Date · Number | |||||
| 3.1 | Amendment to Certificate of Designations, Preferences and Rights of Series B Convertible Preferred Stock of Mangoceuticals, Inc., submitted to the Secretary of State of Texas on June 27, 2024 | 8-K | 3.2 | 7/2/2024 | 001-41615 |
| 3.2 | Certificate of Amendment to Certificate of Formation, as amended and restated of Mangoceuticals, Inc., filed with the Secretary of State of Texas on October 8, 2024 | 8-K | 3.1 | 11/11/2024 | 001-41615 |
| 4.1 | Common Share Purchase Warrant dated June 28, 2024 (500,000 shares), granted to Platinum Point Capital LLC | 8-K | 4.1 | 7/2/2024 | 001-41615 |
| 4.2 | Common Share Purchase Warrant dated June 28, 2024 (1,000,000 shares), granted to Platinum Point Capital LLC | 8-K | 4.2 | 7/2/2024 | 001-41615 |
| 10.1 | Omnibus Amendment Agreement No. 1 dated June 27, 2024, entered into between Mangoceuticals, Inc. and Platinum Point Capital LLC | 8-K | 10.2 | 7/2/2024 | 001-41615 | |
| 10.2 | Master Distribution Agreement dated July 2, 2024 and entered into on July 9, 2024, by and between Mangoceuticals, Inc. and ISFLST, Inc. (ISFLST) | 8-K | 10.1 | 7/11/2024 | 001-41615 | |
| 10.3# | $150,000 Promissory Note issued by Mangoceuticals, Inc. in favor of Cohen Enterprises, Inc. | 8-K | 10.1 | 10/22/2024 | 001-41615 | |
| 10.4# | Consulting Agreement dated November 11, 2024, and effective October 1, 2024, by and between Mangoceuticals, Inc. and Eugene M. Johnston | 8-K | 10.1 | 11/12/2024 | 001-41615 | |
| 31.1* | Certification of Principal Executive Officer pursuant to Exchange Act Rule 13a-14(a) | X | ||||
| 31.2* | Certification of Principal Financial Officer pursuant to Exchange Act Rule 13a-14(a) | X | ||||
| 32.1** | Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350 | X | ||||
| 32.2** | Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350 | X | ||||
| 101.INS | Inline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document | X | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | X | ||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | X | ||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | X | ||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | X | ||||
| 101.LAB | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X | ||||
| 104 | Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set | X | ||||
- Filed herewith.
** Furnished herein.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.